

RECEIVED  
CENTRAL FAX CENTER

006/006

NOV 15 2006

ALTERNATIVE TO PTO/8896a (07-05)

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/803,109
		Filing Date	March 17, 2004
		First Named Inventor	David COOK
		Art Unit	1651
		Examiner Name	S. Saudier
Sheet 1 of 1	Attorney Docket Number	282172000602	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
2	1.	US-6,143,490-A	11-07-2000	Cook et al.	
2	2.	US-6,177,441-B1	01-23-2001	Cook et al.	
2	3.	US-6,410,219-B1	06-25-2002	Cook et al.	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at <http://www.uspto.gov> or MPEP 601.04. \*Owner Office that issued the document, by the two-letter code (WPO Standard 07.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 18 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, casting, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
	6/14/07



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	282172000602
-------	---	----	---	------------------------	--------------

## Complete If Known

Application Number	10/803,109
Filing Date	March 17, 2004
First Named Inventor	David COOK
Art Unit	1651
Examiner Name	S. Saudier
Attorney Docket Number	282172000602

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2006-0115466-A1	06-01-2006	Stassinopoulos	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	<sup>4</sup>
	2.	WO-96/40857-A1	12-19-1996	Steritech, Inc.		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<sup>2</sup>
	3.	Al-Harbi, M.M. et al. (1997). "Gentamycin and Cyclosporine Increase Total Soluble Thiols in the Plasma and Lymphocytes of Rats and Perturb Erythrocyte Fragility," <i>Med. Sci. Res.</i> 25:155-157.	
	4.	Awasthi, Y.C. et al. (December 28, 1984). "Purification and Characterization of a New Form of Glutathione S-Transferase from Human Erythrocytes," <i>Biochemical and Biophys. Res. Commun.</i> 125(3):1053-1060.	
	5.	Högmán, C.F. et al. (March 1993). "Half-Strength Citrate CPD Combined with a New Additive Solution for Improved Storage of Red Blood Cells Suitable for Clinical Use," <i>Vox Sang</i> 65:271-278.	
	6.	Peitz, L.D. et al., eds. (1996). "γ Irradiation of Cellular Blood Components for Prevention of TA-GVHD," In "Graft-Versus-Host-Disease" <i>In Clinical Practice of Transfusion Medicine</i> , Third Edition, Churchill Livingstone, pp. 939-940.	
	7.	Song, P.-S. et al. (June 1979). "Review Article: Photochemistry and Photobiology of Psoralens," <i>Photochem. and Photobio.</i> 29:1177-1197.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature pa-1124664		Date Considered	6/14/07
-------------------------------------	--	--------------------	---------

Substitute for form 1449PTO			Complete If Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/803,109	
			Filing Date	March 17, 2004	
			First Named Inventor	David COOK	
			Art Unit	1651	
			Examiner Name	S. Saudier	
Sheet	2	of	5	Attorney Docket Number	28217200602

39.	WO-97/07674-A1	03-06-1997	Pentose Pharmaceuticals, Inc.		
40.	WO-97/16966-A1	05-15-1997	New York Blood Center, Inc.		
41.	WO-97/18844-A1	05-29-1997	Pall Corporation		
42.	WO-98/30545-A1	07-16-1998	Cerus Corp.		
43.	WO-99/34839-A1	07-15-1999	Cerus Corp.		

\*EXAMINER: Initial information considered, whether or not citation is in compliance with MPEP 609. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Error Office that issued the document, by the two-letter code (WFO Standard ST-2). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WFO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*	
S	44.	Aajmelaeus et al. (1996). "Is There an Unidentified Defense Mechanism Against Infection in Human Plasma," <i>FEBS Letters</i> 384:128-130.		
	45.	Al-Harbi et al. (1997). "Gentamycin and Cyclosporine Increase Total Soluble Ixins in the Plasma and Lymphocytes of Rats and Prolong Erythrocyte Rigidity," <i>Med. Sci. Res.</i> 25:155-157.		MISSING
	46.	Awasthi et al. (1984). "Purification and Characterization of a New Form of Glutathione S-Transferase from Human Erythrocytes," <i>Biochemical and Biophysical Res. Commun.</i> 125:1053-1060.		MISSING
S	47.	Baxt et al. (1978). "Mechanisms of Vesicular Stomatitis Virus-Induced Cytopathic Effects," <i>Virology</i> 72:383-392.		
S	48.	Begleiter et al. (1996). "Chlorambucil in Chronic Lymphocytic Leukemia: Mechanism of Action," <i>Leukemia and Lymphoma</i> 23:187-201 (1996).		
S	49.	Beutler et al. (1982). "The Role of Bone Marrow Transplantation in the Treatment of Acute Leukemia in Remission," <i>Blood</i> 59:1115-1117.		
S	50.	Bolton et al. (1993). "Kinetic Analysis of the Reaction of Methylphenyl with Water, Phosphate, and Glutathione," <i>Drug Metab. Dispos.</i> 21:886-895.		
S	51.	Bolton et al. (1991). "Specificity of Isozymes of Murine Hepatic Glutathione S-transferase for the Conjugation of Glutathione with L-Phenylalanine Mustard," <i>Cancer Research</i> 51:2410-2415.		
S	52.	Bonadonna et al. (1964). "Protection Studies with Sodium Thiosulfate Against Methyl bis-(2-Chloroethyl)amine Hydrochloride (HN2) and its Ethyleniminium Derivative," <i>Clin. Pharm. &amp; Ther.</i> 6:50-64.		
S	53.	Budowsky et al. (1996). "Principles of Selective Inactivation of the Viral Genome: Dependence of the Rate of Viral RNA Modification of the Number of Protonizable Groups in Ethylenimine Oligomers," (1996). <i>Vaccine Res.</i> 5:29-38.		
S	54.	Chong et al. (1990). "Evaluation of Thiol Boron for the Culture of Salmonella Typhi and other Bacteria from Blood," <i>Yonsei Medical Journal</i> 31:163-187.		
S	55.	Colvin et al. (1993). "Role of Glutathione in Cellular Resistance to Alkylating Agents," <i>Adv. Enzyme Regul.</i> 33:19-26.		
S	56.	Colvin et al. (1978). "Alkylating Properties of Phosphoramidate Mustard," <i>Cancer Res.</i> 38:1121-1126.		
S	57.	Devey et al. (1992). "The Effect of Prestorage Irradiation Posttransfusion Red Cell Survival," <i>Transfusion</i> 32:525-528.		
S	58.	Dern et al. (1967). "Studies on the Preservation of Human Blood. II. The Relationship of Erythrocyte Adenosine Triphosphate Levels and other In Vitro Measures to Red Cell		
Examiner Signature	Date Considered		11/14/06	